BOUNDRY, Switzerland, June 19 (UPI) -- Celgene said Tuesday European authorities approved Revlimid for treating multiple myeloma.
The approval, which is for use in combination with dexamethasone, is the first breakthrough oral therapy for multiple myeloma in Europe in more than 40 years.
"The EU approval of Revlimid is an especially important and positive milestone for Celgene, as well as a substantial step forward toward achieving our global mission of making innovative oral therapies available to patients with significant unmet medical needs worldwide," said Aart Brouwer, president of Celgene International.
"We are working diligently with local regulatory authorities to determine next steps for pricing, reimbursement and distribution plans for all EU member states so that Revlimid is available for eligible patients as quickly as possible," Brouwer added.
